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performed to indirectly compare different strategies. METHODS: A pooled analysis 
of all available completed Novo Nordisk randomized clinical trials conducted in 
patients inadequately controlled on basal insulin (five trials) was used to com-
pare indirectly (1) IDegLira (N= 199) with (2) addition of liraglutide to basal insu-
lin (N= 225); (3) basal/bolus (BB) insulin (insulin glargine [IGlar] + insulin aspart) 
(N= 56); or (4) up-titration of IGlar (N= 329). All trials had comparable inclusion/
exclusion criteria, baseline characteristics and titration targets (in strategy 2 the 
basal insulin could not be up-titrated beyond baseline dose). Patient-level data 
were analyzed using multivariable statistical models with baseline heterogeneity 
accounted for using explanatory variables. RESULTS: For strategies 1–4, at end-of-
study (26 or 52 weeks) change in A1C (%) was –1.7, –1.3*, –1.4* and –1.0* respectively; 
change in body weight (kg) was –2.9, –3.5, +4.0* and +1.2*; mean daily basal insulin 
dose (U) was 37.8, 36.6, 62.4* and 60.7*; confirmed hypoglycemia rate (events/100 
patient-years) was 122.8, 124.4, 1060.8* and 286.1* (*p< 0.05 vs. IDegLira). Responder 
rates (percent of patients) were: with A1C < 7.0%: 64.7, 47.1*, 52.8 and 31.9*; with 
A1C < 7.0% and no hypoglycemia: 45.6, 35.5, 5.0* and 15.6*; with A1C < 7.0% and 
no hypoglycemia or weight gain: 39.1, 33.2, 0 and 7.7*. IDegLira was significantly 
better than strategies 3 and 4 for A1C reduction, weight reduction, insulin dose 
and hypoglycemia rate. Responder rates were greater with IDegLira versus strategy 
4. Results with IDegLira were similar (most endpoints) or better than those for 
strategy 2. CONCLUSIONS: These results suggest that IDegLira is more effective, 
with lower hypoglycemia rates, than up-titrated basal insulin or BB in patients 
uncontrolled on basal insulin.
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OBJECTIVES: To assess the relative efficacy of CANA, an inhibitor of sodium glu-
cose co-transporter 2, versus GLP-1 agonists, in second and third line for the 
treatment of T2DM patients, using NMA. METHODS: A systematic review of ran-
domized, controlled trials and Bayesian NMA were conducted to compare HbA1c 
lowering of CANA versus the GLP-1 agonists liraglutide and exenatide. NMAs 
were conducted separately by background treatment (metformin or metformin 
plus sulfonylurea) and trial duration (26/52/104 weeks). Networks were based on 
treatment- and dose-specific nodes. Non-informative priors were used. Relative 
efficacy was evaluated based on absolute differences in HbA1c reductions and 
Bayesian probabilities. RESULTS: In dual therapy, trials were identified reporting 
HbA1c reduction versus baseline at Weeks 26 (n= 8), 52 (n= 6), and 104 (n= 2). At 
Weeks 26 and 52, CANA 300/100mg had greater (Week 26: Δ = –0.17%/–0.28%) to 
similar (Week 52: Δ = –0.03%/0.09%) reductions versus exenatide 5µg, and lower/
similar versus exenatide 10µg (Week 26: Δ = 0.22%/0.10%). Reductions were greater 
for liraglutide 1.8/1.2mg, with differences versus CANA ranging between 0.20% and 
0.61%. At 104 weeks, reductions were similar for CANA 100mg (Δ = 0.04%/0.02%) 
and greater for CANA 300mg (Δ = 0.13%/0.11%) compared to liraglutide 1.2/1.8mg. 
In triple therapy, 5 trials reporting HbA1c reduction at Week 26 were identified 
to compare CANA versus liraglutide 1.8mg and exenatide 10/5µg. Reductions for 
CANA 100mg were similar to exenatide 5µg (Δ = –0.02%) and lower versus exena-
tide 10µg and liraglutide 1.8mg (Δ = –0.24% and –0.33%, respectively). Reductions 
for CANA 300mg were greater versus exenatide 5µg, and similar versus exenatide 
10µg and liraglutide 1.8mg (Δ = –0.01% and 0.08%). CONCLUSIONS: NMA results 
for dual therapy suggest increasing relative efficacy of CANA over time versus 
GLP-1 agonists, with CANA 300mg reaching similar HbA1c reductions as GLP-1 
agonists at 104 weeks. NMA results for triple therapy suggest at least similar 
efficacy for CANA 300mg.
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OBJECTIVES: Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, 
is an effective and well-tolerated therapy in patients with type 2 diabetes mellitus 
(T2DM) in clinical trials. The objective of this study was to evaluate the impact of 
CANA on glycemic control in a real-world population. METHODS: A retrospective 
cohort analysis of adult patients with T2DM was conducted using 2013 data from 
the Inovalon MORE2 Registry, which consists of commercial, managed Medicare 
and Medicaid medical, pharmacy and laboratory claims. Patients with T2DM ≥ 18 
years of age with ≥ 60 days of canagliflozin supply and HbA1c test results within 120 
days pre- and ≥ 60 days post their first observed canagliflozin prescription fill were 
included. Patients with other types of diabetes, enrollment gaps and missing data 
were excluded. The difference between HbA1c levels pre- and post-canagliflozin was 
measured by a paired-t test. A subgroup analysis of patients with HbA1c> 7% at base-
line was also conducted. RESULTS: Of the 268 patients eligible patients with a claim 
for canagliflozin in 2013, 70% of patients received a 100mg dose. Median follow-up 
time to HbA1c measurement was 106 days. Mean (SD) age was 56.8 yrs (8.7), and 57% 
were male. The majority of the patients (63%) were covered by commercial payers. 
Mean HbA1c pre-canagliflozin was 8.3% (95% CI: 8.2%, 8.5%) and post-canagliflozin 
was 7.6% (95% CI: 7.5%, 7.8%). Mean difference in HbA1c pre-post was 0.7% (p< 0.001). 
In the subset of patients with HbA1c> 7% at baseline (81%), the mean difference 
pre-post canagliflozin was 0.9% (95% CI: 0.8%, 1.1%), p< 0.001. CONCLUSIONS: In a 
real-world setting, patients with T2DM had improved glycemic control as measured 
by HbA1c after receiving canagliflozin. HbA1c lowering in patients with baseline 
HbA1c> 7% was similar to the HbA1c improvement for all adults. The HbA1c results 
were generally similar to those observed in clinical trials.
socioeconomics, comorbidities and service year, patients receiving anti-diabetic 
medication were not associated with higher risk of dementia compared to non-
users (Odds Ratio [OR], 1.23; 95% confidence interval [CI], 0.94-1.62). We also found 
that exposure to specific anti-diabetic drugs were not related to the risk of devel-
oping dementia:metformin only (OR, 1.06; 95% CI, 0.69-1.64), sulfonylurea only (OR, 
1.04; 95% CI, 0.78-1.40), insulins only (OR, 0.77; 95% CI, 0.40-1.48), thiazolidinedione 
only (OR,0.77; 95% CI, 0.41-1.45). CONCLUSIONS: Use of anti-diabetic drugs, such 
as insulins, metformin, sulfonylurea and thiazolidinedione, are not associated 
with an altered risk of dementia among elderly.
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OBJECTIVES: Clinical studies suggest that adult type 2 diabetes (T2D) patients 
treated with the once-daily GLP-1 receptor agonist (RA) liraglutide 1.2 and 1.8mg 
achieve significant improvements in glycemic control and body weight with low 
risk of hypoglycemia. The objective of this study is to identify factors that predict 
clinical and economic outcomes associated with liraglutide therapy in a real-world 
setting. METHODS: Using the MarketScan® Laboratory Database, A1C outcomes and 
diabetes-related costs were evaluated in T2D patients initiating liraglutide (index 
event) between January 2010 and June 2012. Patients (N= 417) were required to have 
≥ 1 post-index claim for liraglutide and valid A1C values at baseline and within 
±45 days of the end of 6 months follow-up. Patients previously treated with GLP-1 
RAs or insulin, or evidence of type 1 diabetes, pregnancy or gestational diabetes 
at any time during the study period were excluded. Achievement of glycemic con-
trol (A1C < 7%) and diabetes-related costs were evaluated. Multivariable regression 
was used to identify significant (p< 0.05) predictors of glycemic control and to esti-
mate diabetes-related costs. RESULTS: Factors associated with increased odds of 
achieving A1C< 7% were early initiation (0-1 background oral anti-diabetics (OADs) 
vs. ≥ 2), adherence to liraglutide (proportion of days covered (PDC) ≥ 80%), pres-
ence of diabetic retinopathy or a disorder of lipid metabolism. Early initiation (0-1 
background OADs vs. ≥ 2) and higher out-of-pocket share of pharmacy costs were 
associated with significantly lower total diabetes-related costs at follow-up. Factors 
associated with significantly higher post-index total diabetes-related costs were 
higher baseline A1C, pre-index use of sulfonylureas, and the presence of diabetic 
retinopathy. The indicated impact of gender on clinical and economic outcomes, in 
this specific sample, varied by age. CONCLUSIONS: Predictors of glycemic control 
and diabetes-related costs among T2D patients treated with liraglutide in clinical 
practice include early liraglutide initiation, adherence, certain comorbidities and 
gender (age dependent).
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OBJECTIVES: In clinical trials, GLP-1 receptor agonists (GLP-1RA) dosed daily or 
once weekly (QW) have been shown to reduce HbA1c in patients with poorly 
controlled type 2 diabetes (T2D). However, little data exists on the real-world 
effectiveness of GLP-1RA in patients who have not attained HbA1c < 7.0% while on 
oral therapy. We evaluated glycemic response with GLP-1RA to inform decisions 
about initiating a GLP-1RA based on glycemic control. METHODS: This histori-
cal cohort study included adult T2D patients naïve to insulin and GLP-1RA in a 
national electronic medical record database initiating exenatide QW or liraglutide 
once daily between 2/1/2012 and 3/31/2013 (index date) with baseline HbA1c ≥ 7%. 
Changes in HbA1c from baseline to 6 months and 12 months were identified, as 
was the proportion with follow-up HbA1c < 7.0%. Outcomes were also assessed 
in patients with baseline HbA1c ≥ 9%. Paired t-tests and chi-square tests were 
used to test for significance of HbA1c change and proportion with HbA1c < 7% 
at follow-up. RESULTS: There were 1,474 patients initiating either exenatide 
QW (N= 376) or liraglutide (N= 1,098). Mean (SD) age was 57(11) years; 49.9% were 
female. Mean baseline HbA1c was 8.6%(1.4) overall and 10.2%(1.1) for the subset 
of 476 patients with baseline HbA1c ≥ 9%. At 6 months, mean HbA1c reduction 
was -0.9%(1.5) overall and -1.8%(1.8) in patients with baseline HbA1c ≥ 9% (p< .001 
for both). HbA1c reduction was similar at 12 months at -0.7%(1.5) overall and 
-1.5%(1.9) in patients with baseline HbA1c ≥ 9.0% (p< .001 for both). At 12 months, 
the proportion attaining HbA1c < 7.0% was 25.8% overall and 13% in patients with 
baseline HbA1c ≥ 9%. CONCLUSIONS: GLP-1RA treatment was associated with a 
significant reduction in HbA1c for up to 12 months in a real-world setting in all 
patients; results were more pronounced when baseline HbA1c ≥ 9%. GLP-1RAs may 
be considered in insulin-naïve patients with poorly controlled T2D.
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OBJECTIVES: IDegLira is a once-daily combination of insulin degludec (IDeg) 
and liraglutide. Trials directly comparing IDegLira with alternative strategies for 
intensifying basal insulin are ongoing. While awaiting results, this analysis was 
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oral agents only (43%), and 25% contained insulin. Of patients using CANA in com-
bination with other AHAs, 20% discontinued use of at least 1 AHA during follow-
up. CANA index dose was 100mg for 65% of the population and 300mg for the 
remainder; 30% of patients initially observed on CANA 100mg titrated to 300mg. 
Among patients with A1C ≥ 7.0% at baseline, the proportion of patients with A1C 
< 7% and < 8% increased from 0% (baseline) to 21% (follow-up) and 30% (baseline) to 
61% (follow-up), respectively; those with A1C ≥ 9.0% decreased from 33% (baseline) 
to 16% (follow-up). CONCLUSIONS: CANA was often prescribed as add-on therapy 
to multiple AHAs with one-fifth of patients discontinuing use of other AHAs after 
CANA was added to their treatment regimen. In patients with uncontrolled A1Cs, 
their A1Cs improved following treatment with CANA.
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OBJECTIVES: Given the progressive nature of T2DM, treatment is often characterised 
by gradual intensification, ultimately requiring multiple daily insulin injections. 
CANA and DAPA are agents with activity on SGLT2 that may delay the need for 
insulin. Network meta-analyses (NMAs) have found that CANA 300 mg lowers HbA1c 
more than DAPA in dual and triple therapy. Mechanistic differences support these 
results. Specifically, CANA 300 mg has been shown to reduce the renal threshold for 
glucose excretion more than DAPA 10 mg, resulting in 25% greater 24-hour urinary 
glucose excretion. In addition, unlike DAPA, CANA 300 mg may transiently block 
intestinal SGLT1, delaying glucose absorption and reducing postprandial glucose. 
This study evaluates differences in time to insulin initiation using CANA versus 
DAPA as dual and triple therapy in the Irish healthcare setting. METHODS: A vali-
dated model (ECHO-T2DM) was used to simulate 40-year costs and outcomes asso-
ciated with canagliflozin (100 mg, titrated to 300 mg in patients requiring tighter 
glycaemic control) compared to DAPA (10 mg). Insulin rescue therapy was initiated 
when HbA1c exceeded 7.5%. The CANA RCTs and the NMAs were sourced for ini-
tial patient characteristics and treatment effects, respectively. RESULTS: In dual 
therapy, insulin rescue was delayed by 1.7 years on average for CANA titrated to goal 
(4.8 years) versus DAPA (3.1 years). In triple therapy, insulin therapy was delayed by 
1.8 years on average for CANA titrated to goal (5.1 years) versus DAPA (3.3 years). 
Much of the difference was driven by the ability to titrate to CANA 300 mg for addi-
tional glycaemic control. CONCLUSIONS: These simulations suggest that treatment 
with CANA versus DAPA could delay insulin initiation by 55% in both dual and triple 
therapy. This difference may translate into delays in undesirable health outcomes 
and the financial burden associated with injectables in actual practice.
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OBJECTIVES: The use of insulin analogues for the treatment of diabetes mellitus 
type 1 (DM1) has been widespread, but the real therapeutic benefits need more 
evidences. The aim of this study was to compare the efficacy and safety of insulin 
analogues with human insulin preparations in the treatment of DM1. METHODS: 
Systematic review with meta-analysis of randomized controlled trials (RCTs) avail-
able in PUBMED, LILACS, CENTRAL (accessed February/2014), including manual and 
gray literature search. The meta-analysis was performed using Review Manager® 
5.2 software using random effects model. Outcomes considered were: concentra-
tion(%) of glycated hemoglobin (Hb1Ac), blood or plasma glucose concentrations 
and occurrence of hypoglycemic episodes. Risk of bias was assessed according the 
recommendations of the Cochrane Collaboration. RESULTS: In a total of 36,673 
publications achieved, 35 studies were included: 14 studies compared glargine with 
NPH, 02 (Glargine vs. Detemir), 08 (NPH vs. Detemir), 04 (regular insulin vs Aspart), 
06 (regular insulin vs. Lispro) and 01 (Regular Insulin vs. Glulisine). The insulin 
analogues showed no differences (p< 0,05) compared to human insulin prepara-
tions in relation to Hb1Ac (except Aspart vs regular insulin: favored Aspart) and 
occurrence of hypoglycemic episodes (except Detemir vs. NPH: favored Detemir). 
Glargine, Detemir and Lispro compared to human insulin preparations showed 
slightly improved fasting or post-prandial blood glucose concentrations, however 
this outcome had no ability to influence the overall glycemic control measured by 
Hb1Ac. Most studies showed poor methodological quality and conflicts of inter-
est. CONCLUSIONS: There is poor evidence for the recommendation of first-line 
therapy using analogues instead of human insulin preparations, which efficacy and 
long-term security is better known. The analogues for the treatment of DM1 should 
be better assessed on randomized clinical trials with good methodological quality, 
as well as review of pharmacovigilance data and observational studies in order to 
assess the long-term safety profile.
PDB19
MetforMin anD intensive lifestyle intervention for Pre-DiaBetes - 
systeMati review of efficacy
Fujii R.K.1, Junqueira M.1, Restrepo M.2, Turatti L.A.3
1Merck Serono, SÃ£o Paulo, Brazil, 2Merck Serono, Bogota, Colombia, 3FMUSP, SÃ£o Paulo, Brazil
OBJECTIVES: Individuals with an A1C between 5.7% and 6.4%, impaired fasting glu-
cose (from 100mg/dl [5.6mmol/l] and 125mg/dl [6.9mmol/l] or glucose impaired toler-
ance (oral glucose tolerance test [2-hour] between 140mg/dl [7.8mmol/l] and 199mg/dl 
[11.0mmol/l]), classified as having prediabetes are at increased risk for development 
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OBJECTIVES: Dipeptidyl peptidase-4 inhibitors (DPP4I) include sitagliptin, saxaglip-
tin, vildagliptin and linagliptin. Except for linagliptin, dosage adjustments based 
on renal function are recommended to avoid adverse events (e.g., hypoglycemia). 
However, data on the effect of DPP4I on hemoglobin A1c (HbA1c) in patients with 
renal impairment is sparse. This meta-analysis seeks to determine the effect of 
DPP-4I on HbA1c in patients with chronic kidney disease (CKD). METHODS: Multiple 
databases using the generic name of each DPP4I plus the following search terms 
“renal”, “renal impairment”, chronic kidney disease”, “dialysis”, were queried for 
clinical trial data. Qualitative assessment and quantitative analyses were per-
formed. RESULTS: Eleven citations met inclusion criteria. Studies included 1,704 
participants (10.7% on dialysis), 48-79 years of age, 56% men, 56% Caucasians. Four 
studies compared DPP4I with sulfonylurea (glipizide or glimepiride), five compared 
DPP4I with placebo, two compared DPP4I with placebo for initial 12-weeks and then 
switched to sulfonylurea for 40-42 weeks. Meta-analysis showed DPP-4I caused a 
modest but significant reduction in HbA1c of 0.46% [95% Confidence Interval (CI) 
-0.58, -0.33], p< 0.00001, (I2= 12%), over 12-54 weeks (in patients not on dialysis). In 
placebo-comparator studies, reduction in HbA1c over 12-24 weeks was -0.54% [95%CI 
-0.67, -0.40], p< 0.00001, without heterogeneity. In sulfonylurea-comparator studies, 
DPP-4I did not significantly reduce HbA1c at week 24 (-0.09 [95%CI -0.26, 0.09]) but 
caused a small but significant reduction by weeks 52-54 (-0.19% [95%CI -0.37, -0.00], 
p= 0.04), without heterogeneity. In patients on dialysis, with either comparator (pla-
cebo or glipizide), DPP4I did not significantly reduce HbA1c after 52-54 weeks (0.11 
[95%CI -0.20, 0.41]). CONCLUSIONS: DPP4I in patients with moderate-severe renal 
impairment is associated with a modest reduction of HbA1c versus placebo, but 
not when compared with sulfonylureas or when used in patients on dialysis. It is 
unclear if this modest reduction is worth the high cost of DPP4I in patients with CKD.
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OBJECTIVES: Type 2 diabetes is a progressive disease and most patients experience 
deterioration in glycemic control over time necessitating the use of combination 
therapy. We sought to determine the comparative efficacy and safety of third-line 
antidiabetic agents in patients with type 2 diabetes after failure of metformin 
and TZD therapy. METHODS: We performed a literature search of MEDLINE and 
CENTRAL through May 2014 and included randomized controlled trials (RCTs) of 
≥ 12-weeks duration evaluating the addition of a noninsulin agent in patients with 
type 2 diabetes inadequately controlled on stable, optimized metformin and TZD 
therapy (≥ 1500mg metformin and ≥ 50% maximum TZD dose for ≥ 4 weeks). Network 
meta-analysis was performed on identified trials. Endpoints of interest were 
changes from baseline in HbA1c, body weight, systolic blood pressure (SBP); and 
the risk of hypoglycemia, urinary (UTI) and genital tract infection (GTI). RESULTS: 
Eleven RCTs evaluating dipeptidyl peptidase-4 (DPP-4) inhibitors (linagliptin, sitag-
liptin), sulfonylureas (SUs), (glibenclamide, glimepiride), glucagon-like peptide-1 
(GLP-1) analogs (exenatide, liraglutide, dulaglutide, taspoglutide) and sodium glu-
cose cotransporter-2 (SGLT2) inhibitors (canagliflozin, empagliflozin) were included. 
All agents analyzed reduced HbA1c vs placebo (range, 0.55-1.17%). All SUs were 
associated with significant weight gain (range, 3.31-7.29 kg), while significant weight 
loss was seen with all GLP-1 analogs (range, 1.53-2.2 kg) and SGLT-2 inhibitors (range, 
2.08-2.95 kg). A reduction in SBP was seen in canagliflozin and GLP-1 analogs (range, 
2.39-5.05 mmHg). The relative risk (RR) of confirmed hypoglycemia was significantly 
increased with dulaglutide, exenatide and glimepiride vs. placebo (RR range, 2.65-
6.17); and was higher (RR> 1.0) than all other agents except linagliptin. No agent 
reported an increased risk for UTI or GTI vs. placebo. CONCLUSIONS: In conclu-
sion, when added to stable, optimized metformin and TZD therapy, all noninsulin 
antidiabetic agents reduced HbA1c, but differed in their effects on body weight, 
hypoglycemia and SBP.
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OBJECTIVES: Canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor, 
has been shown to improve glycemic control in clinical trials. This study describes 
the treatment patterns of antihyperglycemic agents (AHAs) among patients with 
T2DM receiving CANA in a real-world setting. METHODS: This retrospective cohort 
study used data from a large US health plan for commercial and Medicare Advantage 
enrollees age ≥ 18 years with T2DM that filled CANA between April-October 2013 
(first 7 months on the market). Six-month baseline and follow-up data were evalu-
ated. Concomitant AHA use was defined as having at least 2 prescriptions, with 1 fill 
during baseline and 1 fill on/after CANA initiation without a ≥ 60-day therapy gap. 
Discontinuation was defined as a ≥ 60-day therapy gap. RESULTS: In this sample 
(n= 4017), 43% were female and average age was 56 years; 826 had baseline and 
follow-up A1C available. Approximately 30% of patients used CANA concomitantly 
with 1 other AHA, while 50% used CANA concomitantly with ≥ 2 other AHAs; the 
remaining 20% used CANA alone. The most common baseline regimens comprised 
